Literature DB >> 27838587

The effect of a liver-X-receptor ligand on bleomycin induced pulmonary fibrosis in mice.

Ying Shi1, Qiongju Chen2, Haijun Yan1, Wei Gu1.   

Abstract

The liver-X-receptors have shown anti-fibrosis ability in several animal models. Our purpose was to investigate the effect of LXRs in bleomycin induced lung fibrosis in mice. Bleomycin was intratracheally delivered to mice. Some mice were administered a LXR agonist, T0901317. Then mice were evaluated for the development of lung inflammation and fibrosis. T0901317 was able to attenuate the inflammation and fibrosis induced by bleomycin. T0901317 treatment evidently abolished the high level of TGF-β1 and inhibited NF-κB DNA-binding activity in lung. So LXRs may attenuate the progressing of lung fibrosis, providing a potential treatment of IPF. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bleomycin; Liver X receptors; Pulmonary fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27838587     DOI: 10.1016/j.intimp.2016.10.016

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  3 in total

1.  Therapeutic molecular targets of SSc-ILD.

Authors:  Yun Zhang; Jörg Hw Distler
Journal:  J Scleroderma Relat Disord       Date:  2020-01-22

2.  Reduction of fibrosis and immune suppressive cells in ErbB2-dependent tumorigenesis by an LXR agonist.

Authors:  Gao Sheng; Hongyan Yuan; Lu Jin; Suman Ranjit; Julia Panov; Xun Lu; Moshe Levi; Robert I Glazer
Journal:  PLoS One       Date:  2021-03-29       Impact factor: 3.240

Review 3.  The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.

Authors:  Michael B Fessler
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.